التفاصيل البيبلوغرافية
| العنوان: |
Isatuximab plus pomalidomide and dexamethasone in patients with relapsed/refractory multiple myeloma in real‐world: The retrospective IMAGE study. |
| المؤلفون: |
Decaux, Olivier1,2 (AUTHOR), Fontan, Jean3 (AUTHOR), Perrot, Aurore4 (AUTHOR), Karlin, Lionel5 (AUTHOR), Touzeau, Cyrille6 (AUTHOR), Schulmann, Samantha7 (AUTHOR), Manier, Salomon8 (AUTHOR), Belhadj, Karim9 (AUTHOR), Trebouet, Adrien10 (AUTHOR), Zunic, Patricia11 (AUTHOR), Schiano De Colella, Jean‐Marc12 (AUTHOR), Castel, Brice13 (AUTHOR), Van De Wyngaert, Zoé14 (AUTHOR), Pica, Gian Matteo15 (AUTHOR), Tiab, Mourad16 (AUTHOR), Kuhnowski, Frédérique17 (AUTHOR), Bouketouche, Malek18 (AUTHOR), Rigaudeau, Sophia19 (AUTHOR), Benramdane, Riad20 (AUTHOR), Tekle, Christina21 (AUTHOR) |
| المصدر: |
European Journal of Haematology. May2024, p1. 8p. 4 Illustrations, 2 Charts. |
| مستخلص: |
Background Methods Results Conclusion IMAGE is a retrospective cohort study of patients enrolled in early access programs (EAPs) in France with relapsed/refractory multiple myeloma (RRMM) receiving isatuximab with pomalidomide and dexamethasone (Isa‐Pd).Patients aged ≥18 years with RRMM who received ≥1 dose of Isa under the EAPs between July 29, 2019 and August 30, 2020 were included. Effectiveness endpoints included progression‐free survival (PFS) and response rates. Verbatim terms for adverse events (AEs) were coded using the Medical Dictionary for Regulatory Activities and not graded for severity.A total of 294 and 299 patients were included in the effectiveness and safety populations, respectively. IMAGE included patients who received one prior line of treatment (10.2%) and were daratumumab‐refractory (19.1%). At median follow‐up of 14.2 months, median PFS in the effectiveness population was 12.4 months (95% CI 9.0–15.0). Overall response and very good partial response rates were 46.3% and 27.9%, respectively. Subgroup analyses reflected similar results. In the safety population, 26.4% of patients reported at least one AE; the most common any‐grade AE was neutropenia (9.4%).IMAGE demonstrated Isa‐Pd had meaningful effectiveness in median PFS and depth of response and no new safety signals in a real‐world context, consistent with clinical trial results. [ABSTRACT FROM AUTHOR] |
| قاعدة البيانات: |
Academic Search Index |
